REGENXBIO Inc.
General ticker "RGNX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $520.7M (TTM average)
REGENXBIO Inc. follows the US Stock Market performance with the rate: 41.6%.
Estimated limits based on current volatility of 3.9%: low 8.47$, high 9.15$
Factors to consider:
- Earnings expected soon, date: 2026-05-11 bmo
- Total employees count: 353 (-66.1%) as of 2024
- Top business risk factors: Operational and conduct risks, Clinical trial delays and efficacy/safety demonstration, Product recalls, Cybersecurity threats, Regulatory and compliance
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.13$, 22.33$]
- 2026-12-31 to 2027-12-31 estimated range: [8.51$, 19.15$]
Financial Metrics affecting the RGNX estimates:
- Positive: with PPE of -3.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -16.93 <= 0.07
- Positive: -4.45 < Investing cash flow per share per price, % of -2.17
- Positive: 19.49 < Shareholder equity ratio, % of 22.68 <= 42.60
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term RGNX quotes
Long-term RGNX plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $90.24MM | $83.33MM | $170.44MM |
| Operating Expenses | $358.37MM | $316.67MM | $331.64MM |
| Operating Income | $-268.13MM | $-233.35MM | $-161.20MM |
| Non-Operating Income | $4.48MM | $6.24MM | $-32.68MM |
| Interest Expense | $6.86MM | $12.66MM | $45.01MM |
| R&D Expense | $232.27MM | $208.52MM | $228.30MM |
| Income(Loss) | $-263.65MM | $-227.10MM | $-193.88MM |
| Taxes | $-0.15MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-263.49MM | $-227.10MM | $-193.88MM |
| Stockholders Equity | $311.74MM | $259.65MM | $102.73MM |
| Assets | $573.97MM | $465.99MM | $453.03MM |
| Operating Cash Flow | $-218.41MM | $-173.12MM | $-123.96MM |
| Capital expenditure | $9.96MM | $2.44MM | $2.41MM |
| Investing Cash Flow | $190.94MM | $103.45MM | $-15.87MM |
| Financing Cash Flow | $-34.97MM | $92.68MM | $116.77MM |
| Earnings Per Share** | $-6.02 | $-4.59 | $-3.76 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.